Journal of Infectious Diseases Publishes ContraFect Corporation’s Scientific Research

YONKERS, NY, May 13, 2014 – ContraFect Corporation, a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, announced today that the Journal of Infectious Diseases, JID 2014:209 (1 May) has published the results of its scientific research on its lead compound, CF-301.

This entry was posted in Recent Development News: Q2 - 2014. Bookmark the permalink.